CellCentric's epigenetic portfolio moves forward
This article was originally published in Scrip
Executive Summary
CellCentric's innovative business model continues to pay dividends following the signing of an enlarged agreement with the Chinese contract R&D firm HD Biosciences (HDB).This will move the project from a screening exercise into a drug discovery operation. Financial details were not disclosed.